Recruiting
Yervoy Pregnancy Surveillance Study - CA184-487
Updated: 15 February, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment Exclusion Criteria: - Women whose ipilimumab exposure is outside the window of pregnancy exposure - Pregnancies for which there is only paternal exposure to Yervoy Other protocol defined inclusion/exclusion criteria could apply